June 24 (Reuters) - Abbisko Cayman 2256.HK said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly LLY.N.

The agreement will allow both firms to collaborate on the discovery and development of medicines across multiple targets, with Abbisko Therapeutics eligible for development, regulatory and commercial milestone payments of up to $1.9 billion.